Drug Target Review

NOVEMBER 1, 2023

Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. The Journal of Cell Biology. Structure–Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode. Umezu-Goto M, Kishi Y, Taira A, et al. 2017;2017:1–15.

Clinical Trials 134

Clinical Trials Small Molecule Trials Disease 134

Drug Target Review

DECEMBER 21, 2023

mRNA biology has become widely recognised as a new “drug mine” RNAi drugs are in the market and mRNA vaccines, initially developed for Covid-19, are already in trials for cancer. All of these are novel targets to be explored in small molecule drug discovery as well as for improving the efficacy of mRNA vaccines.

Disease 105

Disease Small Molecule Vaccine Drugs 105

Drug Target Review

JULY 31, 2023

If you are collaborating with all of these different people, if you’re providing the small molecule tools for lots of different projects, how can I evaluate you as an independent scientist?” When I started in academics 16 years ago, I heard the question, “how can I evaluate your work if you are not the last author?

DNA 98

DNA Small Molecule Science Cell Biology 98

The Pharma Data

OCTOBER 19, 2020

At Aduro, he was responsible for all manufacturing and supply chain activities for the company’s biologics and small molecules and managed a transatlantic team. in Cell Biology from Utrecht University. Prior to Aduro, Dr. van de Laar held various development and manufacturing positions at MSD (trademark of Merck & Co.,

Trials 40

Trials Small Molecule Cell Biology Clinical Trials 40

NIH Director's Blog: Drug Discovery

APRIL 11, 2017

Researchers soon began screening a chemical library and its more than 380,000 traditional drug candidates to find the right small-molecule inhibitor, the preferred compound in drug discovery. Missing was the usual pocket-shaped active site, where a traditional small molecule can readily bind and block function.

Small Molecule 52

Small Molecule Science Drug Development Disease 52

Elrig

APRIL 29, 2024

Fascinated by the potential of AI in medical research, I transitioned to BenevolentAI in early 2023 as a Biology Project Leader. There, I supported AI-enabled DD efforts in their small molecule portfolio. Driven by an interest in drug discovery Millie joined AstraZeneca after completion of her PhD at the end of 2020.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Codon

APRIL 2, 2023

An open-source FACS automation system for high-throughput cell biology. Cell Systems. Read Small-molecule aptamer for regulating RNA functions in mammalian cells and animals. Read The FDA is reviewing a “controversial cell therapy for ALS,” developed by BrainStorm Cell Therapeutics.

DNA 52

DNA RNA Engineering Licensing 52

Codon

APRIL 30, 2023

Read Stem cells were induced to form insulin-secreting pancreas cells and then transplanted into diabetic mice, where they successfully restored glucose levels. Nature Cell Biology. Read Microbes in the wild ‘talk’ to their neighbors by emitting, and sensing, small chemicals. Cell Systems.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

Read Stem cells were induced to form insulin-secreting pancreas cells and then transplanted into diabetic mice, where they successfully restored glucose levels. Nature Cell Biology. Read Microbes in the wild ‘talk’ to their neighbors by emitting, and sensing, small chemicals. Cell Systems.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

FEBRUARY 28, 2023

I felt like a scientist for the first time, and I began to grasp the “numbers of biology” (many calculations in this essay come from that course and another textbook, Cell Biology by the Numbers.) Without mathematics, I learned, biology is naked; we can only comprehend it at arm's length.

RNA 52

RNA DNA Cell Biology Small Molecule 52

Codon

APRIL 16, 2023

Nature Cell Biology. Read *Open-endedness in synthetic biology: a route to continual innovation for biological design. Read Aer Therapeutics, a University of California, San Francisco lab spinout developing an inhaled small molecule drug for chronic obstructive pulmonary disease, raised $36 million in a Series A.

Engineering 52

Engineering DNA RNA Science 52